Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Raymond James Maintains Outperform on Marvell Tech, Lowers Price Target to $50

Raymond James analyst Srini Pajjuri maintains Marvell Tech (NASDAQ:MRVL) with a Outperform and lowers the price target from $54 to $50.

byBenzinga Newsdesk

March 3, 2023

1 minute read

Raymond James analyst Srini Pajjuri maintains Marvell Tech (NASDAQ:MRVL) with a Outperform and lowers the price target from $54 to $50.

AN2 Therapeutics Q3 EPS $(0.59) Up From $(3.35) YoY

By Benzinga Newsdesk

Today, 2:49 AM

AN2 Therapeutics (NASDAQ:ANTX) reported quarterly losses of $(0.59) per share. This is a 82.39 percent increase over losses of $(3.35) per share from the same period last year.

ANTX

JP Morgan Upgrades RPM International to Neutral, Raises Price Target to $100

By Benzinga Newsdesk

Today, 2:49 AM

JP Morgan analyst Jeffrey Zekauskas upgrades RPM International (NYSE:RPM) from Underweight to Neutral and raises the price target from $85 to $100.

RPM

Tesla Faces Indefinite Delay On Supply Of Lithium Chemicals From Piedmont

By Madhukumar Warrier

Today, 2:49 AM

Tesla Inc. (NASDAQ: TSLA) is facing an indefinite delay on the supply of lithium chemicals from Piedmont Lithium Inc. (NASDAQ: PLL), Reuters

PLL

BofA Upgrades Patterson-UTI Energy After Q3 Beat

By Priya Nigam

Today, 2:49 AM

Patterson-UTI Energy, Inc. (NASDAQ: PTEN) reported an earnings beat for the third quarter, while six of the 10 oilfield service (OFS) companies covered missed expectations, according to BofA Securities.

PTEN

Raymond James Maintains Outperform on Marvell Tech, Lowers Price Target to $50

Related Posts

AN2 Therapeutics Q3 EPS $(0.59) Up From $(3.35) YoY

JP Morgan Upgrades RPM International to Neutral, Raises Price Target to $100

Tesla Faces Indefinite Delay On Supply Of Lithium Chemicals From Piedmont

BofA Upgrades Patterson-UTI Energy After Q3 Beat